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Innate immunity is critical in the early containment of influenza A virus (IAV) infection and
surfactant protein D (SP-D) plays a crucial role in innate defense against IAV in the lungs.
Multivalent lectin-mediated interactions of SP-D with IAVs result in viral aggregation,
reduced epithelial infection, and enhanced IAV clearance by phagocytic cells. Previous
studies showed that porcine SP-D (pSP-D) exhibits distinct antiviral activity against IAV
as compared to human SP-D (hSP-D), mainly due to key residues in the lectin domain of
pSP-D that contribute to its profound neutralizing activity. These observations provided
the basis for the design of a full-length recombinant mutant form of hSP-D, designated
as “improved SP-D” (iSP-D). Inspired by pSP-D, the lectin domain of iSP-D has 5
amino acids replaced (Asp324Asn, Asp330Asn, Val251Glu, Lys287Gln, Glu289Lys) and
3 amino acids inserted (326Gly-Ser-Ser). Characterization of iSP-D revealed no major
differences in protein assembly and saccharide binding selectivity as compared to hSP-
D. However, hemagglutination inhibition measurements showed that iSP-D expressed
strongly enhanced activity compared to hSP-D against 31 different IAV strains tested,
including (pandemic) IAVs that were resistant for neutralization by hSP-D. Furthermore,
iSP-D showed increased viral aggregation and enhanced protection of MDCK cells
against infection by IAV. Importantly, prophylactic or therapeutic application of iSP-D
decreased weight loss and reduced viral lung titers in a murine model of IAV infection
using a clinical isolate of H1N1pdm09 virus. These studies demonstrate the potential
of iSP-D as a novel human-based antiviral inhalation drug that may provide immediate
protection against or recovery from respiratory (pandemic) IAV infections in humans.
Keywords: antiviral agent, influenza A virus, innate immunity, surfactant protein D, collectin, pandemics,
recombinant expression, lung infection
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INTRODUCTION
Influenza is an infectious respiratory disease, caused by influenza
A viruses (IAVs), that affects a wide range of natural hosts
including humans, pigs and birds. Worldwide, annual epidemics
result in 3 to 5 million cases of severe illness and about 300.000
to 650.000 deaths (1). Moreover, novel IAVs have potential to
cause influenza pandemics like the most recent outbreak in 2009
that was estimated to have caused between 100.000 and 400.000
deaths globally in the first year alone (2). Pigs, in particular, are
susceptible to co-infection by both avian and human IAVs and
as a consequence, novel reassorted IAVs can be introduced to the
human population as illustrated by the swine-origin pandemic
flu of 2009 (3). During the early stages of IAV respiratory
infection, the innate immune response plays a key role in limiting
IAV replication and thereby spread of infection, modulating the
inflammatory and adaptive responses. Distinct responses cause
the differences in pathogenicity that result from infection by
pandemic vs. seasonal IAVs (4). Given the important role of
pigs in being susceptible for co-infection by a broad range of
IAVs and since persistence of infection readily occurs in this
animal species (5), studies were initiated to investigate porcine
pulmonary innate responses against IAV in more detail.
Pulmonary innate defense involves the secretion of soluble
proteins that are capable of neutralizing IAV infectivity, several
of which are members of the “collectin” family (6). These
collagenous lectins include surfactant protein D (SP-D), a large
cruciform-shaped glycoprotein that exhibits strong antiviral
properties, as demonstrated by many in vitro and in vivo studies
[reviewed in (7)]. The dodecameric X-shaped configuration of
SP-D results from the assembly of four trimeric arms, each
of which contains an N-terminal collagenous domain that
clusters three mannose-type Ca2+-dependent lectin domains (or
carbohydrate recognition domains, CRDs) at the C-terminus
of each arm. These trimeric CRDs facilitate multivalent, high-
affinity interactions with the spike proteins on IAV, in particular
the hemagglutinin (HA), a trimeric glycoprotein that mediates
attachment of IAV to host cells via sialic acid (SA) receptor-
mediated attachment (8, 9). This type of inhibition is highly
conserved and described for SP-Ds from different animal species
and is referred to as “β-type inhibition” since it involves
Ca2+-dependent lectin-mediated binding between the CRD
and high-mannose glycans present on HA. The importance of
this interaction is demonstrated by loss of antiviral activity
in the absence of calcium ions and by experiments with
poorly glycosylated IAVs that are (more) resistant to SP-D-
mediated neutralization (10–13). Upon binding to SP-D, several
mechanisms of IAV neutralization are initiated that include viral
aggregation, blocking IAV attachment to the epithelium, and
opsonization of IAV that results in enhanced clearance of IAV
Abbreviations: 326GSS, pSP-D-specific insertion of Gly-Ser-Ser adjacent to residue
Gly-326 of the SP-D consensus sequence; CRD, carbohydrate recognition domain;
HA, hemagglutin; HAI, hemagglutination inhibition; HAU, hemagglutinating
units; hSP-D, human SP-D; IAV, influenza A virus; iSP-D, improved SP-D; MDCK,
Madin-Darby canine kidney; NCRD, neck region plus CRD from SP-D; pSP-
D, porcine SP-D; SA, sialic acid; SP-A, surfactant protein A; SP-D, surfactant
protein D.
by alveolar macrophages and neutrophils (7). These antiviral
properties depend, to a large extent, on the state of assembly
of SP-D since many studies have demonstrated that trimeric
SP-D is much less active in neutralizing IAV as compared to
fully assembled, dodecameric or higher order multimers of SP-
D (14). Importantly, human SP-D (hSP-D) lacks the ability to
bind pandemic IAVs due to limited glycosylation of the HA head
regions. Studies in mice infected with SP-D resistant pandemic
IAVs demonstrated that this leads to increased morbidity and
mortality (15).
The potency of SP-D to bind and neutralize IAVs varies
between different animal species and it was demonstrated
previously that porcine SP-D (pSP-D) exhibits distinct antiviral
activity in vitro as compared to SP-Ds from other animal species
including hSP-D and mouse SP-D (10, 16, 17). Furthermore,
unlike hSP-D, pSP-D is able to bind and neutralize pandemic
IAVs (10, 16). The mechanisms that underlie the exceptional
IAV-neutralizing properties of pSP-D have been studied in detail
and it was shown that this mainly involves distinct structural
features located in the CRD of pSP-D. pSP-D is glycosylated with
a highly sialylated N-linked glycan at Asn303 (Figure 1A) on
its CRD that results in calcium-independent “γ-type inhibitor”-
like activity, mediated by SA residues that interact with the
conserved SA-receptor binding site located on the HA of all
IAVs. In vitro studies with pSP-D isolated from bronchoalveolar
lavage as well as studies with recombinant pSP-D demonstrate
that this “γ-inhibitor” mechanism not only enhances the overall
activity but that it also broadens the range of viral strains that
can be inhibited, including strains that are not neutralized by
hSP-D (10, 16, 19, 20). However, studies with N-deglycosylated
full-length pSP-D showed that its distinct antiviral activity can
only in part be attributed to the presence of the N-linked
glycan in the CRD of pSP-D (10, 21). Sequence analysis of
pSP-D aligned with hSP-D (Figure 1A) and crystallographic
investigations with trimeric neckCRD (NCRD) recombinant
fragments of pSP-D (22) revealed the presence of a unique
tripeptide extension of the long loop in the CRD of SP-D,
referred to as “326GSS” near the lectin site (Figures 1A–C,
shaded in magenta). Molecular dynamics simulations of this
fragment complexed with oligomannose showed that this flexible
tripeptide adopts a more stable conformation upon sugar binding
and that the insertion possibly interacts with more distal portions
of the branched mannoside. Docking studies with tri-antennary
octamannose underlined that with a terminal mannoside bound
in the lectin site, several contacts between another arm of the
oligomannose showed potential to interact with the 326GSS-
loop. Since this loop is absent in hSP-D, this could explain the
distinct Ca2+-mediated interactions between pSP-D and viral
glycans as compared to hSP-D (22). Analysis of the crystal
structure of the CRD of pSP-D also indicated that Asn324 and
Asn330 might add to the flexibility of the 326GSS-insertion by
altering the conserved structural calcium sites located between
the long and short loops of the CRD, thereby increasing its ability
to interact with non-terminal saccharides. In addition to the
326GSS-insertion at the lectin-site, several other porcine-specific
residues on the surface of the CRD of pSP-D play a potential
role in increased affinity of pSP-D for viral glycans. Furthermore,
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FIGURE 1 | Design of the NCRD of iSP-D. (A) Amino acid sequence alignment of the CRD sequences from human SP-D (hSP-D, Genbank accession code: X65018)
and porcine SP-D (pSP-D, AF132496). Residue numbering according to hSP-D sequence. Dashes indicate spaces that are inserted to maximize the identity across
the alignment. The residues that comprise the neck region of hSP-D are underlined (residues #203-#235). Dots indicate identical residues between hSP-D and
pSP-D. Dashes indicate spaces inserted to maximize the identity across the alignment. Mutated residues in hSP-D that generate iSP-D are shaded in magenta, blue
and green. The N-glycosylation site at #303 in the CRD of pSP-D is indicated (orange box). The secondary structural regions are indicated as gray arrows (β-sheets)
and dark gray bars (α-helices), deduced from the crystal structure of rat SP-A (18). SP-D groove regions (delineated), cysteines (bold) and cysteine bridges (black
dotted lines/arrows), and key residues necessary for coordination of Ca2+-ions and hydroxyl groups of oligosaccharides (asterisks) are also indicated. (B) Tertiary
protein structure of the neckCRD of SP-D. Shown is a ribbon diagram of the NCRD of hSP-D (blue, PDB accession no. 3G81) overlayed with that of pSP-D (brown,
PDB accession no. 4DN8). A bound α-methyl mannoside as stick representation in yellow is visualized to illustrate the lectin binding pocket and 3 calcium ions are
shown as black spheres. Modifications of hSP-D present in iSP-D are highlighted with deviating colors: the 326GSS-insertion (magenta), and the Asp324Asn and
Asp330Asn mutations (blue; also indicated with blue arrows). Location of the N-linked glycan in the CRD of pSP-D is shown in orange sticks. (C) Surface
representation of the neckCRD of pSP-D. Shown is the neck region (light blue) and the CRD (brown) of pSP-D (PDB accession no 4DN8) with porcine-specific
residues mutated into hSP-D highlighted in different colors: the 326GSS-insertion (magenta), and the Man8-contact residues Glu251, Gln287, and Lys289 (green).
Calcium ions are only partly visible on the surface (black).
several non-lectin site residues on the surface of the CRD of
pSP-D: Glu251, Gln287, Asn288 (conserved in hSP-D), and
Lys289, form a bulge in the surface (Figures 1A,C, shaded green)
that hypothetically may interact with several mannose residues
from another arm of the octamannose (22). Taken together, the
antiviral and crystallographic studies on pSP-D have shed light on
the structural requirements that might explain its extraordinary
potential to neutralize IAVs.
Previously it was shown that fully functional highly pure
recombinant SP-Ds can be produced using CHO- or HEK293-
cell expression systems (21, 23). This facilitates the potential
value of SP-D-based drugs as a novel therapeutic or prophylactic
approach to fight influenza in humans more effectively.
Furthermore, recombinant approaches provide a window of
opportunity to modify human-based innate defense mediators,
like hSP-D, to generate derivatives that may target and neutralize
a broader range of IAVs much more effectively as compared
to their wildtype counterparts. SP-D-based antivirals are
attractive multifunctional candidate drugs because, in addition
to direct antiviral activity against a broad range of IAVs, SP-
D promotes phagocytosis, down-modulates lung inflammation,
and exhibits antibacterial and antifungal properties (24–26). To
limit immunogenicity of protein-based therapeutic drugs, the
application of human proteins is preferred. This study describes
the development of “improved SP-D,” referred to as iSP-D,
that is based upon full-length hSP-D and modified in its CRD
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by introducing 8 porcine-specific residues that are potentially
important for the distinct activity of pSP-D as hypothesized
in our previous studies and described above (22, 27). These
mutations are highlighted in different colors in Figure 1 and
include insertion of the 326GSS-loop (magenta), substitution
of Asp324 and Asp330 by asparagine residues (blue), and
introduction of the bulge-forming residues Glu251, Gln287, and
Lys289 (green). After several rounds of site-directedmutagenesis,
the hSP-D mutant iSP-D was successfully expressed in HEK293
cells. After purification by mannan affinity and gel filtration,
the protein was characterized for its structural and saccharide-
binding properties which were shown to be very similar to
those of pSP-D and hSP-D. Several antiviral characteristics of
iSP-D were assessed in vitro against a broad panel of IAVs
isolated from different host species. These included binding to
HA (hemagglutination inhibition assays, HAI), aggregation of
IAV particles, and SP-D-mediated protection of MDCK cells
against IAV infection. Overall, the strongest antiviral activity was
expressed by pSP-D but iSP-D was shown to have significantly
stronger antiviral activity as compared to hSP-D and proved
to be active against hSP-D-resistant IAVs including pandemic
IAVs. The potential of iSP-D as a novel antiviral intervention
was further demonstrated by assessing its protective effects in
vivo. To this end, a mouse IAV infection model was developed to
demonstrate the therapeutic and prophylactic potential of iSP-D
against infection by a clinical isolate of pandemic H1N1 virus.
MATERIALS AND METHODS
Reagents
TOPO T/A cloning kit was supplied by Invitrogen (Breda, The
Netherlands), and the Quikchange II site-directed mutagenesis
kit by Stratagene (Bio-connect, Huissen, The Netherlands).
Qiagen spin miniprep and midiprep kits, gel extraction kit,
and proofstart DNA Polymerase were all provided by Qiagen
Benelux BV (Venlo, The Netherlands). All restriction enzymes
were supplied by New England Biolabs (van Westburg, Leusden,
The Netherlands). The expression vector pUPE101-01 was
provided by U-Protein Express (Utrecht, The Netherlands). The
ToxinSensorTM Chromogenic LAL Endotoxin Assay Kit was
purchased from Genscript (Piscataway, NJ, USA).
Construction of Full-Length iSP-D
Full-length recombinant iSP-D was generated based upon the
full-length hSP-D cDNA clone provided by Dr. E. C. Crouch
[WashingtonUniversity, St. Louis, USA; (8)]. This clone was used
as a template for PCR cloning into pCR4-TOPO to introduce
a BsmBI/BamHI (5′-end) and NotI (3′-end) restriction site to
accommodate subcloning in expression vector pUPE-101.01, as
previously described for construction of the expression clone
for full-length pSP-D (21). The expression vector pUPE-101.01
is a modified version of the pTT3 expression vector (28). The
full-length human SP-D clone in PCR4-TOPO was used as a
template to introduce the 8 porcine-specific aa residue mutations
in 5 subsequent rounds of site-directed mutagenesis by overlap
extension PCR using the Quikchange II site-directedmutagenesis
kit. After each round of site-directed mutagenesis, the obtained
hSP-D PCR4-TOPO clone was verified by sequence analysis
and used as a template to perform the next round of site-
directed mutagenesis. Mutagenesis primer pairs used are listed
below; all DNA sequences described are 5′ to 3′ with desired nt
mutations underlined. Round 1, 326GSS insert: 1FOR, GAG CCC
AAC GAT GAT GGC GGC AGC AGC GGG TCA GAG GAC
TGT GTG GAG with 1REV, CTC CAC ACA GTC CTC TGA
CCC GCT GCT GCC GCC ATC ATC GTT GGG CTC. Round
2, Asp324Asn: 2FOR, CA GGG GAG CCC AAC AAT GAT
GGC GGC AGC AGC GGG TCA GAG GAC with 2REV, GTC
CTC TGA CCC GCT GCC GCC GCC ATC ATT GTT GGG
CTC CCC TG. Round 3, Asp330Asn: 3FOR, GGC GGC AGC
AGC GGG TCA GAG AAC TGT GTG GAG ATC TTC ACC
with 3REV, GGT GAA GAT CTC CAC ACA GTT CTC TGA
CCC GCT GCT GCC GCC. Round 4, Val251Glu: 4FOR, G
ATT TTC AAG ACA GCA GGC TTT GAA AAA CCA TTT
ACG GAG GCA CAG with CTG TGC CTC CGT AAA TGG
TTT TTC AAA GCC TGC TGT CTT GAA AAT C. Round 5,
Lys287Gln + Glu289Lys (both mutations were generated in a
single round of site-directed mutagenesis): 5FOR, G CAA CAG
CTG GTC GTA GCT CAG AAC AAG GCT GCT TTC CTG
AGC ATG with 5REV, CAT GCT CAG GAA AGC AGC CTT
GTT CTG AGC TAC GAC CAG CTG TTG C. After sequence
verification, the pCR4-TOPO insert containing all 8 aa residue
mutations were digested with BsmBI/NotI, gel purified, and
transferred to pUPE101.01 as described (21). The full-length
recombinant collectins pSP-D and hSP-D were constructed as
published (21).
Expression, Purification, and Biochemical
Characterization of SP-Ds
All the recombinant SP-D’s were expressed in HEK293 cells
and purified by mannan affinity followed by gel filtration
chromatography as published (21). SDS-PAGE analysis and
Western blot analysis were performed as described in detail
for the characterization of NpSP-D (19). Endotoxin levels were
determined with the ToxinSensor LAL assay kit (Genscript,
Piscataway, NJ) and endotoxin values of all SP-D preparations
were below 50 pg/µg protein.
Structural characterization of purified SP-D was analyzed by
Atomic Force Microscopy (AFM). SP-D stock solutions (range
1–10µg/ml) were diluted 100x in PBS and applied on freshly
cleaved mica and left for 5min to allow for protein adherence.
After rinsing with PBS followed by de-ionized water, the mica
samples were left to dry at room temperature, immediately
followed by AFM analysis using a Bruker Multimode IIIA AFM
(112 Robin Hill Road, Santa Barbara, CA 93117, USA). AFM was
performed in “TappingMode” using a cantilever of type Olympus
AC240TS (nominal stiffness 2 N/m). Scan size was 1 × 1 µm2,
scan rate was 1.5Hz and images were recorded with 512 × 512
pixels. Data shown is raw data except for the default line-by-line
background subtraction.
Saccharide binding affinity of all SP-Ds was tested by
measuring the competition of SP-D binding to BSA/mannan-
coated 96-well plates in the presence of various saccharides as
previously described (29). The following mono- or disaccharides
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were tested: N-acetylmannosamine, L-fucose, D-galactose, D-
glucose, myo-inositol, maltose, D-mannose, and fructose. Results
were expressed as IC50 values, the concentrations of the various
saccharides required for 50% inhibition of collectin binding
to BSA-mannan. Experiments were carried out three times
in duplicate.
Influenza A Virus Strains
Hemagglutination inhibition studies were performed with 31
IAVs. These were selected based on their subtype and species
of origin and included avian, swine and human IAVs of three
subtypes: H1N1, H3N2, and H5N1. Details of these strains
are listed in Table 2. Viruses were propagated in Madin-Darby
Canine Kidney (MDCK) cells as described previously (30).
After low speed centrifugation, the infectious virus titers of
the culture supernatants of the infected MDCK cells were
determined as described previously (30) and virus stocks
were stored at −80◦C until use. The three recombinant
H5N1 viruses, A/Indonesia/5/05, A/VietNam/1194/04 and
A/HongKong/156/97 were prepared as 6+2 reassortant
strains by reverse genetics as described previously (31).
The basic cleavage site in the HA protein was deleted by
site-directed mutagenesis.
Viral aggregation was performed with the pandemic
A/Aichi/68 (H3N2) strain which was obtained from the
American Type Culture Collection (ATCC, Manassas, VA).
After growth in the chorioallantoic fluid of 10-day-old chicken
eggs, the virus was purified on a discontinuous sucrose gradient
as described previously (20). The virus was dialyzed against
PBS to remove sucrose, aliquoted, and stored at −80◦C.
After thawing, the viral stocks contained 5 × 108 infectious
focus–forming units/ml.
In vivo efficacy studies were performed with pandemic
A/California/2009 (H1N1) E9-6714, a clinical isolate obtained
from the University Medical Center Groningen (Groningen, The
Netherlands). After initial amplification onMDCK cells, the virus
was further propagated in the chorioallantoic fluid of 10-day-old
chicken eggs as described above.
Hemagglutination Inhibition Assay
Binding of SP-D to the viral HA and interference with binding
of the virus to its receptor was assessed by HAI as previously
published (16). Two-fold dilutions of SP-D or peanut agglutinin
(negative control, Sigma Aldrich, Schnellldorf, Germany), which
was included as a negative control, were made using Dulbecco’s
phosphate buffered saline containing PBS containing 1mM of
CaCl2 and 0.5mM of MgCl2, PBS-CM (Gibco, Grand Island,
USA). To 100 µl of the diluted SP-D, 2 hemagglutination units
(HAU) of the respective viruses diluted in PBS-CM were added.
After 1 h, 25 µl of 1% turkey erythrocytes were added. The
hemagglutination patterns were read after 3 h of incubation at
room temperature. The highest SP-D concentration tested was
1,000 ng/ml, except for the assays that compared activity between
oligomers and trimers (only strain A/PuertoRico/8/34 (H1N1);
highest concentration SP-D tested: 2,000 ng/ml). As a negative
control, the experiment was also performed in PBS without
CaCl2 to demonstrate the Ca
2+-dependency of the SP-D activity.
Statistically significant differences were calculated by two-tailed
paired Student’s t-test.
Viral Aggregation
SP-D-mediated aggregation of IAV particles was determined
with A/Aichi/68 (H3N2) and carried out as described previously
(32). For both hSP-D and iSP-D, preparations of 4.0µg/ml were
mixed with a suspension of virus in a final volume of 1ml.
During stirring, the light transmission was monitored for 12min
using an SLM/Aminco 8000C spectrofluorimeter (excitation and
emission wavelengths were 350 nm). Viral aggregation resulted
in an increase in light transmission, and results were expressed
as a percentage of control light transmission at t = 0. As a
negative control, virus without addition of SP-D was included.
Experiments were performed five times, and statistical analysis
was performed with the Student’s t-test.
IAV Infection Reduction Assay
To investigate SP-D-mediated inhibition of infection we used an
infection reduction assay as previously described (16). Briefly:
100 µl of increasing concentrations of SP-D (0–2,000 ng/ml)
were incubated for 1 h at room temperature with 100 µl of
the respective virus preparations containing 3,000 TCID50
diluted in PBS containing 1mM of CaCl2 and 0.5mM of
MgCl2 (PBS-CM). Peanut agglutinin, which was included
as a negative control, failed to reduce the number of cells
infected with any of the IAVs used (data not shown). The 4
viruses used in this study were: A/Netherlands/602/09 (H1N1),
A/Commonteal/Netherlands/10/00 (H1N1), A/Swine/849/93
(H3N2), and A/Mallard/NL/1/07 (H3N2). Subsequently,
the mixture was transferred to MDCK cells, incubated for
1 h at 37◦C and after washing, the cells were incubated for
24 h at 37◦C in culture medium without trypsin to prevent
secondary infection of cells by IAV. After trypsinization,
the obtained cell suspensions were fixed and stained
with FITC-labeled monoclonal antibodies against viral
nucleoprotein (DAKOCytomation, Glostrup, Denmark).
After washing, the cells were analyzed by flow-cytometry using
the DIVA software.
In vivo Efficacy of iSP-D Against IAV
Infection
To elucidate the protective effect of iSP-D against IAV infection
in vivo, we used a mouse infection model using 6–8 weeks
old female BALBC/cOlaHsd mice (supplied from Harlan, The
Netherlands). Upon arrival, the animals had an acclimatization
period of one week; at the start of the experiment the mice
had a weight of about 20 g. Mice were randomly allocated
to experimental groups. Virus and/or SP-D (both 25 µl) was
pulmonary administered with a microsprayer (PennCentury,
Wyndmoore, PA, USA) just above the tracheal bifurcation
after tracheal intubation with a 20G infusion cannula. Viral
challenge was performed with a clinical isolate of H1N1pdm09
virus (A/California/E9/09; obtained from the Department of
Medical Microbiology, Clinical Virology, University Medical
Center Groningen, Groningen, The Netherlands) at a dose of
1 × 103 TCID50 in PBS. SP-D preparations were administered
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at a concentration of 1 mg/ml dissolved in 5mM Hepes (pH
7.4), 0.9% NaCl, and 2mM CaCl2. Three independent in
vivo experiments were performed with 4 groups each (group
size: 6 animals) to investigate the antiviral potential of iSP-D
immediately delivered after viral challenge (exp I), to compare
the antiviral potential of two different batches of iSP-D with
wildtype hSP-D (exp II) and to study the antiviral effect of
iSP-D delivered 1 day after or before viral challenge (exp
III). After initiation of the experiments, the animals were
evaluated once-a-day and scored for appearance, behavior,
weight and movement. An ethical end-point was considered if
a cumulative weight loss of ≥15% or a weight loss of ≥10%
FIGURE 2 | Characterization of iSP-D and comparison with other SP-Ds. (A) Reducing (left) and non-reducing (right) SDS-PAGE (12%) and Coomassie staining of
purified full-length SP-Ds. (B) Western blot analysis of reduced and non-reduced hSP-D and iSP-D, followed by immunodetection with rabbit anti-human SP-D
antibodies and goat anti-rabbit HRPO conjugate. The different bands visible in the non-reducing lanes are due to the presence of various oligomeric forms of SP-D
that typically occurs upon non-reducing SDS-PAGE analysis of fully assembled SP-D. (C) Analysis of SP-Ds by Atomic Force Microscopy in ambient conditions after
deposition on mica and scanning in tapping mode. The high points are colored lighter and lower points darker—full scale, black to white is 2 nm.
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on a single day was observed. The experiments were terminated
3 days after virus challenge and the lungs were collected for
virus recovery. All animal experiments were approved by the
Institutional Animal Care and Use Committee of the University
of Groningen (IACUC-RUG) and were approved under number
DEC 6864.
Immunohistochemical analysis was performed to investigate
viral infection of the lungs using the IAV strain and route of
administration as described above. Lung tissue was collected in
10% neutral-buffered formalin and fixed for 48 h followed by
embedding in paraffin and sectioned at 5µm. Sections were
de-paraffinized prior to antigen retrieval with 0.1% Pronase
(Merck) in PBS for 10min at 37◦C. Endogenous peroxidase
activity was blocked with 3% H2O2 in PBS for 10min and
after blocking with serum (15min, 10% Normal Goat Serum,
Jackson Immunoresearch) to minimize non-specific binding,
sections were incubated with either mouse anti-influenza A
nucleoprotein, clone HB-65 [ATCC; (33)] or Mouse IgG2A
(Thermo Fisher Scientific, Breda, The Netherlands) at 1:100
dilution for 60min at room temperature. The incubation
with DakoEnvision goat anti-mouse antibody (Agilent
Technologies, Amstelveen, The Netherlands) was according
to the manufacturer’s protocol. Finally, slides were developed
with AEC+chromogenic substrate for 30min, counterstained
with Mayer’s hematoxylin for 30 s and mounted using aqueous
mounting media.
Virus recovery: after weighing the lungs were homogenized
in PBS (pH 7.4) and centrifuged at 1,200 rpm for 10min. The
obtained supernatants were snap-frozen in liquid nitrogen and
stored at −80◦C until use. Lung virus titers were determined
by infecting MDCK cells grown in 96-well plates with serial
dilutions of the lung homogenate supernatants. After 2 h
the medium was replaced by medium containing 7.5µg/ml
TPCK-treated trypsin (Merck, Darmstadt, Germany) and plates
were incubated for 72 h at 37◦C, 5% CO2. Supernatants were
then transferred to a V-bottom 96-well plate and guinea pig
erythrocytes (0.3% final concentration) were added. After 2 h
the virus titers in the lungs were read as the dilutions at which
hemagglutination still occurred. Next, the log10 virus titer was
calculated per gram of lung tissue. Statistical comparisons
between experimental groups were made by two-tailed
Student’s t-test.
RESULTS
Expression and Characterization of SP-D
Preparations
All full-length SP-Ds were produced using transient transfection
of HEK293E cells as described previously for recombinant
full-length pSP-D and hSP-D (21). The SP-D-containing cell
medium was subjected to Ca2+-dependent mannan affinity
chromatography followed by gel filtration chromatography to
separate different states of SP-D oligomerization (oligomers
vs. trimers). Mannan affinity chromatography did not reveal
differences in Ca2+-dependent mannan-binding efficiency
between the three recombinant SP-Ds. Transient expression
of the newly developed iSP-D construct, however, resulted
in significantly higher expression levels (average yield 15–20
mg/l) as compared to pSP-D and hSP-D (2.5–5 mg/l) with a
similar ratio of oligomeric vs. trimeric SP-D (approximately 2:1,
w/w). Analysis of the oligomeric fractions of all three SP-Ds by
reducing SDS-PAGE showed a major monomeric band of ∼
50 kDa for pSP-D, while hSP-D and iSP-D migrated as slightly
smaller monomers of ∼ 45 kDa (Figure 2A, left lanes). Under
non-reducing conditions, all SP-Ds showed multiple bands of
increasing molecular weights with a distinct major band at >500
kDa, especially for pSP-D for which all bands ran at slightly
higher molecular weight as compared to those from hSP-D and
iSP-D (Figure 2A, right lanes). Western blot analysis of reduced
and non-reduced hSP-D and iSP-D followed by immunostaining
with rabbit anti-human SP-D showed identical patterns of
immunoreactivity with band sizes corresponding to those
obtained after Coomassie staining (Figure 2B). The oligomeric
fractions of the three SP-D preparations were also subjected to
structural analysis by Atomic Force Microscopy (Figure 2C).
Several different oligomeric forms could be distinguished
for all three SP-Ds that include dodecamers (four-armed
structures), higher-order oligomers (“fuzzy-ball”-like structures)
and intermediate forms. Of note, the structures present in
the iSP-D preparations showed a tendency to become slightly
more contracted upon AFM analysis as compared to pSP-D
and hSP-D.
The saccharide binding properties of the three SP-Ds were
compared using a variety of mono- and disaccharides as
competitors for SP-D binding to BSA-mannan coated plates
(Table 1). The IC50 values for each competitor were determined
as concentrations (mM) required to obtain 50% reduction
in SP-D-binding to BSA-mannan. The IC50 values were not
strikingly different for all SP-Ds measured. The order of
preferential glycan binding for pSP-D was almost identical
to what was published previously for natural pSP-D (10).
Overall, no significant differences were observed in carbohydrate
binding profiles between hSP-D and iSP-D and both were
comparable to what was previously determined for hSP-D (10).
The only exception was the IC50-value for myo-inositol which
was three times higher for iSP-D as compared to hSP-D, in
strong contrast with pSP-D which showed highest affinity for
this glycan.
Hemagglutination Inhibition of IAVs by
SP-Ds
The inhibitory activity of pSP-D and hSP-D was compared to
that of iSP-D by assessing the minimal concentration of SP-D
required to prevent hemagglutination induced by IAV for 31
different strains (Table 2). The strains were listed according to
subtype (H1N1, H3N2, and H5N1) and host species from which
the strain was isolated (swine, human or avian). Overall, pSP-D
was the most active inhibitor of hemagglutination by all IAVs
tested with highest activity for human isolates (either H1N1
or H3N2). On average, H3N2 viruses were more susceptible
to pSP-D than H1N1 viruses. In contrast to pSP-D, most of
the IAVs could not be inhibited by hSP-D even at the highest
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TABLE 1 | Comparison of saccharide selectivity of recombinant pSP-D, hSP-D, and iSP-D.
Sugar inhibitor pSP-D hSP-D iSP-D
Myo-Inositol 0.9 (0.4) 5.6 (0.9) 17.3 (2.1)
Maltose 2.0 (0.2) 3.3 (0.5) 4.1 (0.1)
L-Fucose 2.2 (0.8) 3.8 (0.4) 4.3 (0.6)
Fructose 2.8 (1.1) 3.1 (0.1) 4.8 (1.3)
D-Glucose 2.8 (0.8) 4.6 (1.5) 7.8 (1.4)
D-Mannose 4.6 (1.3) 3.6 (0.5) 5.3 (2.1)
D-Galactose 6.5 (0.8) 13.5 (4.8) 13.6 (3.4)
ManNAc 8.0 (0.1) 2.2 (0.2) 3.1 (0.7)
Microtiter wells were coated with BSA-mannan and were incubated with SP-Ds in the presence of increasing concentrations of sugars listed. Binding of collectin to BSA-mannan was
measured by immunodetection as described in the Materials and Methods section. Results are expressed as concentrations (mM) of saccharide required for 50% inhibition of SP-D
binding (IC50) to BSA-mannan. Data are averages of three experiments; SD values in parentheses.
dose tested (1,000 ng/ml), except for the human isolates (both
H1N1 and H3N2) which were inhibited by hSP-D in the same
concentration range as by pSP-D with the exception of H1N1
strain A/PuertoRico/8/34 (resistant to hSP-D). Strikingly, the
hSP-D-derivative iSP-D exhibited substantial HAI activity against
all IAVs with statistically significant stronger activity compared
to hSP-D against 15 of the 31 H1N1/H3N2 strains tested. The
overall profile of HAI values obtained for iSP-D was remarkably
similar to that of pSP-D. Three different H5N1 viruses (each virus
n = 1 only) were most resistant for inhibition by all SP-Ds and
only showed some susceptibility for pSP-D, although relatively
high concentrations were required to fully inhibit each of the 3
strains tested (250–500 ng/ml).
Additional HAI experiments were performed using the
comparatively SP-D-resistant strain A/PuertoRico/8/34 (H1N1)
to determine the importance of oligomerization for SP-Ds HAI
properties (Figure 3). The assay was performed with higher
SP-D starting concentrations (2,000 ng/ml) as compared to the
HAI data shown in Table 1. Again, fully assembled pSP-D was
most profound in inhibiting this IAV strain, slightly more
effective compared to iSP-D while hSP-D was not able to inhibit
A/PuertoRico/8/34 (H1N1). Trimeric SP-Ds were less effective in
HAI as compared to oligomeric SP-Ds. Although pSP-D trimers
still retained most of their HAI activity (3-fold reduction in
activity; 144 ± 52 ng/ml for trimeric vs. 48 ± 29 ng/ml for
oligomeric pSP-D), the iSP-D trimers were much less effective
(almost 13-fold reduction; 1,800 ± 210 ng/ml for trimeric vs.
140 ± 50 ng/ml for oligomeric iSP-D). In the case of hSP-
D, trimers showed no HAI activity against A/PuertoRico/8/34
(H1N1), similar to what was found for hSP-D oligomers.
Anti-IAV Activity of SP-Ds Assessed by
Functional Assays
The ability of SP-D to aggregate IAV particles was determined
using the pandemic A/Aichi/68 (H3N2) strain. Virus incubated
in the presence of 4.0µg/ml hSP-D resulted in aggregate
formation as demonstrated by a gradual increase in light
transmission (black squares, Figure 4). In the presence of the
same amount of iSP-D, aggregation was significantly increased
(75% increase after 12min as compared to hSP-D (white squares,
Figure 4). As a control, incubation of virus in buffer only did not
result in any aggregation.
An infection reduction assay was used to determine the
capacity of SP-D to protect MDCK cells from infection by IAV
with 4 different strains (2 strains of H1N1 subtype and 2 strains
of H3N2 subtype); the anti-IAV activity was expressed as %
inhibition of infection as compared to IAV infection in absence
of SP-D (Figure 5). Peanut agglutinin, which was included as a
negative control for SP-D, did not reduce the number of cells
infected with any of the IAV strains used (data not shown). In
contrast, pSP-D inhibited infection of MDCK cells by all strains
tested and the average minimal dose of pSP-D required to obtain
at least 50% inhibition of infection by IAV was approximately
30 ng/100 µl. In general, higher doses of pSP-D (up to 1,000
ng/µl) resulted in slightly higher percentages of inhibition and
in this cellular infectivity assay, none of the viruses tested
were fully inhibited by pSP-D. Compared to pSP-D, the activity
of hSP-D was substantially lower at all concentrations tested
and the average highest percentage of inhibition observed was
approximately 30%, even at the highest dose of hSP-D. Strikingly,
the infection reducing activity of iSP-D was almost similar to
that of pSP-D and substantially higher compared to that of hSP-
D. Compared to hSP-D, the activity of iSP-D was statistically
significant higher for all concentrations measured except the
lowest concentration tested (2.0 ng/ml).
In vivo Validation of the Antiviral Activity of
iSP-D
The virus inhibiting potential of iSP-D in vivo was assessed
by using a mouse model for influenza and to demonstrate
the protective potential against a human-derived virus strain,
a clinical isolate of pandemic H1N1 virus (E9-6714, named
H1N1pdm09 in the following) was used for inoculation. The
optimal dose and route of administration (either intranasal,
intratracheal, or intratracheal using a microsprayer) for this
pandemic strain was first determined in a pilot experiment (4
animals/group). Results indicated that a dose of 103 TCID50
delivered by the use of pulmonary microsprayer inoculation
resulted in rapid weight loss and broader distribution of the
virus over the lungs as determined by immunohistochemical
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TABLE 2 | Hemagglutination inhibition of IAV by SP-Ds.
H1N1 influenza A viruses SP-D preparation H3N2 influenza A viruses SP-D preparation
pSP-D hSP-D iSP-D pSP-D hSP-D iSP-D
Swine (pandemic 2009) Swine
A/Netherlands/602/09 167 (72) >1,000 (0) 458 (473) A/swine/Oedenrode/7C/96 63 (0) >1,000 (0) 104* (36)
A/Califomia/4/09 161 (94) >1,000 (0) 479 (452) A/swine/Netherlands/849/93 16 (0) >1,000 (0) 8* (0)
Swine (classical) A/swine/Utrecht/4/85 16 (0) >1,000 (0) 16* (0)
A/swine/Shope/11/56 458 (72) >1,000 (0) 583 (382) A/swine/Ukkel/1/84 44 (16) >1,000 (0) 57* (9)
A/swine/Iowa/15/30 750 (354) >1,000 (0) >1,000 (0) Human
A/NewJersey/8/76 60 (5) >1,000 (0) 83* (36) A/Netherlands/348/07 2 (2) 4 (3) 2 (2)
Swine (avian-like) A/Netherlands/548/05 1 (1) 4 (0) 1* (1)
A/swine/Netherlands/25/80 188 (108) >1,000 (0) 375* (217) A/Netherlands/312/03 1 (0) 5 (3) 1 (0)
A/swine/Netherlands/1/87 208 (72) >1,000 (0) 229* (95) A/Netherlands/35/93 16 (0) 833 (289) 52* (63)
Human Avian
A/Netherlands/384/06 9 (2) 89 (33) 17 (10) A/mallard/Netherlands/19/05 26 (9) >1,000 (0) 52* (18)
A/Netherlands/246/08 9 (6) 34 (25) 11 (4) A/mallard/Netherlands/51/08 12 (7) 688 (541) 16 (8)
A/PuertoRico/8/34 313 (165) >1,000 (0) 313* (165) A/mallard/Sweden/57/03 11 (17) >1,000 (0) 26* (9)
A/Netherlands/26/07 36 (36) 83 (36) 21* (16) A/mallard/Netherlands/1/07 18 (12) 385 (532) 10 (4)
A/USSR/90/77 4 (4) 3 (1) 3 (4)
Avian H5N1 influenza A viruses (n = 1)
A/mallard/Netherlands/15/05 146 (95) >1,000 (0) 208* (72) A/HongKong/156/97 (clade 0) 500 >1,000 >1,000
A/mallard/Netherlands/24/06 45 (30) 681 (553) 25 (11) A/Vietnam/1194/0 (clade 1) 250 >1,000 >1,000
A/white fronted
goose/Netherlands/1/07
104 (36) >1,000 (0) 125* (0) A/lndonesia/5/05 (clade 2.1) 250 >1,000 >1,000
A/common
teal/Netherlands/10/00
83 (36) >1,000 (0) 120* (113)
Shown is the inhibitory activity of pSP-D, hSP-D, and iSP-D against a broad panel of IAVs isolated from different animal species (swine, human, avian) and different subtypes (H1N1,
H3N2, and H5N1). Values are lowest concentrations (ng/ml) required to fully inhibit 20 hemagglutination units/ml of the respective viruses diluted in PBS. A value of “>1,000” indicates
no inhibition at the highest SP-D concentrations tested. Assay procedure and details are described in Materials and Methods section. Measurements were performed in duplo (except
for H5N1 viruses: n = 1) and shown is the mean of three independent experiments with standard deviations in parentheses. Statistical analysis by two-tailed paired Student’s t-test (*P
< 0.05 vs. hSP-D).
analysis of lungs 3 days after infection with IAV; representative
images are shown in Figure 6. Viral infection was observed
in bronchiolar epithelial cells (Figures 6A,B) as well as in
in alveolar epithelial cells (Figures 6C,D). It should be noted
that the immunohistochemical analysis could not be used
in a quantitative fashion since measured differences in lung
virus titers and weight development were not noticeable by
immunostaining of the virus in situ.
Using the parameters described above, this infection model
was used to determine the protective value of iSP-D in vivo
(Figure 7). The first experiment was executed by administering
25 µg of iSP-D, immediately before inoculation with IAV, and
included 3 control groups that received buffer only, virus only
or iSP-D only (6 animals/group). All animals were monitored
for changes in body weight and results showed an average
weight loss of 12.5% over 3 days in the mice that were treated
with buffer followed by inoculation with virus (Figure 7A), just
below the ethical end point which was set at a cumulative
weight loss of >15%. In contrast, the mice that were first
treated with iSP-D, followed by inoculation with the same 103
TCID50 dose of H1N1pdm09, did not show any weight loss.
Administration of iSP-D only did not result in any changes in
body weight as compared to treatment with buffer only. In line
with protection from infection-induced weight loss, the iSP-D-
treated mice were also partially protected from virus replication
in the lungs (Figure 7B) since the average lung virus titer in iSP-
D-treated mice was approximately 10 times lower compared to
non-treated mice.
Next, we evaluated whether different batches of iSP-D were
equally effective in protecting from influenza disease symptoms
and virus growth in the lungs. In addition, we compared the
activity of iSP-D with that of hSP-D (Figures 7C,D, respectively).
In this experiment a lower dose of SP-D was administered (5.0
µg/animal) to monitor differences in protective activity between
iSP-D and hSP-D more adequately. Mice that were infected with
IAV after treatment with buffer had a mean weight loss of 12.6%
by day 3. In contrast, the mice treated with iSP-D batch-a had a
maximal weight loss of 5.4% and 3 out of 6 animals did not lose
weight at all (p < 0.0005 vs. control group). The iSP-D batch-
b was slightly more effective since none of the mice developed
more than 0.5% weight loss (p < 0.00005 vs. control group).
The group that received treatment with hSP-D, prior to infection,
resulted in no statistically significant difference in weight loss
compared to the buffer-treated control group (Figure 7C). The
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FIGURE 3 | Effect of SP-D assembly on HAI activity of IAV. The inhibitory
activity of iSP-D, pSP-D and hSP-D was measured for oligomeric structures
and for trimeric subunit structures of SP-D. Increasing concentrations (highest
concentration tested was 2,000 ng/ml) of SP-D were mixed with 2 HAU of IAV
(A/PuertoRico/8/34 (H1N1) strain) and after 1 h erythrocytes were added. After
3 h incubation at room temperature, IAV-induced hemagglutination patterns
revealed the lowest concentration of SP-D required to fully inhibit
hemagglutination by IAV. The assay was performed in PBS containing 1mM of
CaCl2 and 0.5mM of MgCl2. Averages are based upon five independent
experiments.
FIGURE 4 | Aggregation of IAV particles by hSP-D and iSP-D. IAV particles
[strain A/Aichi/68 (H3N2)] were suspended in buffer, mixed at t = 0 with
4.0µg/ml iSP-D or hSP-D (control: virus only). The continuously stirred mixture
was monitored for light transmission during 12min and results are expressed
as % of light transmission at t = 0. Measurements were performed five times
and values are mean ± SEM. Statistical analysis was carried out by the
two-tailed paired Student’s t-test. *p < 0.05 (iSP-D vs. hSP-D).
pattern of observed animal weight loss resulting from treatment
with or without iSP-D or hSP-D was also reflected by lung virus
titers (Figure 7D). Whereas, lung virus titers were significantly
reduced upon treatment with iSP-D (batch-a or -b) as compared
FIGURE 5 | Neutralization of IAV infection by SP-Ds. The infection reduction
assay was used to measure and compare the ability of hSP-D, iSP-D, and
pSP-D to inhibit IAV infection of MDCK cells. Increasing concentrations of
SP-D were mixed with 3,000 TCID50 of 4 different IAV preparations: 2 H1N1
subtype IAVs and 2 H3N2 subtype IAVs. After 1 h pre-incubation at room
temperature, the mixtures were added to MDCK cells, incubated for 1 h at
37◦C, and after washing, the MDCK cells were incubated for 24 h at 37◦C in
medium without trypsin to prevent secondary rounds of infection by IAV. Cell
suspensions, obtained after trypsinization, were fixed and stained for viral
nucleoprotein. After washing the cells were analyzed by flow-cytometry using
the DIVA software. Reduction of infectivity was expressed as the relative
number of cells that became infected according to the formula: % reduction =
1–(% infected cells in presence of SP-D/% infected cells without SP-D)*100%.
Shown is the average value of the 4 different strains analyzed. Statistical
analysis was carried out by the two-tailed paired Student’s t-test. *p < 0.05
(iSP-D vs. hSP-D).
to the control group (buffer only), no statistically significant
reduction was observed when hSP-D was administered prior
to infection.
In the third in vivo validation experiment we aimed to
test the prophylactic and therapeutic potential of iSP-D by
expanding the time-interval (24 h) between drug administration
followed by infection (prophylactic use) and by reversing the
order of administration (infection followed by iSP-D treatment)
to test whether iSP-D contributes to recovery from previously
established IAV infections (therapeutic use). As illustrated in
Figure 7E, 3 days after virus challenge, treatment with iSP-
D either 24 h before infection or 24 h after infection, resulted
in significantly reduced weight loss as compared to control
treatment (virus/buffer or buffer/virus). Determination of lung
virus titers showed that the protective effect of iSP-D was
most profound upon therapeutic application, resulting in a
significantly reduced virus titer (14 times lower) as compared to
the buffer control group (Figure 7F). Only a slight statistically
nonsignificant reduction in virus titer was observed when iSP-
D was administered 24 h before virus challenge as compared
to buffer.
DISCUSSION
The innate immune response is considered crucial for
containment of viral spread at early stages of infection and
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many previous studies, in vitro and in vivo, have shown that
SP-D is known to play an important role in protection against
IAV infection (4). Animal species-specific differences in anti-
IAV activity of SP-D have been demonstrated and may result
from variations in key amino acid residues located in the
CRD near the lectin binding site which facilitates interactions
with glycans exposed on the surface of IAV (11, 34). Porcine
SP-D, in particular, has unique structural features that sets it
apart from all other SP-D species. An N-linked sialoglycan in
the CRD of pSP-D facilitates interactions with the sialic acid
receptor of HA, the spike protein of IAV responsible for viral
attachment to the host epithelium. Follow-up structural studies
with deglycosylated NCRD fragments of pSP-D revealed that its
CRD contains a unique tripeptide loop (326GSS), that most likely
contributes to the distinct lectin-mediated activity of pSP-D
(22). Crystallography and docking studies with octamannose
also revealed 5 other residues that are hypothetically involved
in generating profound anti-IAV activity as displayed by pSP-D:
Asn324 and Asn330 might increase flexibility of the 326GSS loop,
while Glu251, Gln287, and Lys289 are unconserved residues
that could make contact with distal parts of lectin-bound
octamannose (unpublished observations). To investigate to what
extent these porcine-specific residues contribute to the distinct
lectin-mediated antiviral activity of pSP-D, we generated iSP-D,
a hSP-D-based mutant that has 8 amino acid residues in its CRD
modified according to the pSP-D sequence (Figure 1).
After several rounds of site-directed mutagenesis on the full-
length wildtype hSP-D clone, iSP-D was successfully expressed
in HEK293 cells and purified from the cell-free medium as
described for other recombinant SP-Ds (21, 22). The molecular
structure of iSP-D, as analyzed by SDS-PAGE and AFM, was
very similar to that of hSP-D and only small differences were
observed with regard to the spatial arrangement of the oligomeric
arms of iSP-D (slightly more condensed compared to that of
pSP-D and hSP-D). Since the collagen domain of iSP-D is
identical to that of hSP-D, this is most likely due to subtle
differences in sample preparation for AFM analysis. iSP-D
was also characterized by investigating its saccharide binding
properties for various mono- and disaccharides (Table 1). The
overall binding affinity profile of iSP-D was very similar to that
of hSP-D, the only difference observed was its decreased affinity
for myo-inositol. Interestingly, pSP-D showed highest affinity for
this monosaccharide but substitution of porcine-specific residues
into hSP-D did not generate preferential recognition of this
ligand by iSP-D. Previously, it was shown that mutation of
residues that flank the primary carbohydrate recognition site
can have an impact on the saccharide binding selectivity (35–
37). In the case of iSP-D, crystallographic analysis of the NCRD
of iSPD in combination with modeling and/or docking studies
will be required to determine the mechanism that underlies
the difference in affinity observed for myo-inositol. It most
likely involves the additional loop 326GSS and/or the substituted
residues Asn324 and Asn330. Of note, glycan array studies with
a library of natural and synthetic oligosaccharides would be
required to provide more insight on the lectin binding selectivity
and possibly improved affinity of iSP-D toward larger highly
branched glycans, as present on the HA of IAV.
Screening the HAI activity of iSP-D against a panel of IAVs
with different subtypes and host origins enabled us to determine
whether the modifications that were engineered into hSP-D
enhanced its antiviral potential. Furthermore, screening helped
to determine if the mutant iSP-D displayed distinct inhibitory
properties against IAV to the level of what was demonstrated
previously for pSP-D (10, 16). As shown in Table 2, the different
IAV strains showed varying degrees of susceptibility to SP-D-
mediated neutralization for all three SP-Ds tested. However, it
was demonstrated for all strains that the mutant iSP-D exhibited
an overall strong HAI activity, except for the H5N1 strains which
among all IAVs tested were most resistant against all SP-Ds,
including pSP-D. Strikingly, the antiviral activity profile of iSP-
D was highly similar to that of pSP-D and for more than half
of all the 31 strains tested, there was a statistically significant
increase in HAI activity of iSP-D compared to hSP-D. Clearly,
these findings confirmed our hypothesis that the selected 8
porcine-specific residues were important in contributing to the
distinct anti-IAV activity of pSP-D since genetic modification of
hSP-D with these 8 residues, strongly improved the moderate
antiviral activity of wildtype hSP-D. Moreover, the “porcinized”
hSP-D mutant iSP-D expressed HAI activity to a degree that
is in the range of that of pSP-D. Interestingly, the improved
antiviral properties of iSP-D were most pronounced against those
IAV strains that were designated as resistant against inhibition
by hSP-D (no HAI observed with highest concentration tested)
and these included pandemic and avian(-like) strains known to
be resistant for inhibition by hSP-D (15, 38). Most likely, the
improved activity of iSP-D against these strains resulted from
enhanced binding affinity to the small number of mannosylated
glycans present on these strains. In contrast, the more recent
human seasonal H1N1 and H3N2 isolates were most susceptible
for HA inhibition by all SP-Ds. These observations are in line
with previous studies that showed that in time strains circulating
in the human population acquire more glycans on the head
region of the viral HA, most likely due to shielding the HA from
antibody-mediated neutralization (12). As a consequence, these
IAVs are more prone to lectin-mediated binding and subsequent
enhanced neutralization, in contrast to isolates obtained shortly
after introduction in the human population which possess
fewer glycans and are thus more resistant against neutralization
by hSP-D.
Many studies have demonstrated the importance of the
degree of oligomerization for the efficacy of SP-D to bind
and neutralize bacteria and viruses, including IAV (39, 40). In
general, multivalent interactions by (multi)dodecameric SP-D
with multiple IAV particles result in more efficient aggregation
and neutralization of IAV as compared to SP-D trimers, also
demonstrated for pSP-D and hSP-D against a broad panel of IAVs
(16). To investigate possible differences in HAI activity between
trimeric pSP-D, hSP-D and iSP-D, the relatively SP-D-resistant
A/PuertoRico/8/34 (H1N1) strain was used while oligomeric SP-
Ds were included as control. As expected, the oligomeric SP-Ds
were most effective and activity was in the order pSP-D > iSP-
D > hSP-D (Figure 3). In accordance with previous studies, this
IAV strain was found to be resistant for inhibition by oligomeric
hSP-D and, not surprisingly, the generally less active trimeric
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FIGURE 6 | Lung immunohistology of pandemic IAV infection mouse model. Pattern of pandemic IAV-infection in the lungs from mice used as a model for antiviral
efficacy studies with iSP-D. Photomicrographs of hematoxylin-stained tissue sections and immunohistochemically stained sections for detection of influenza viral
nucleoprotein from mice infected with a clinical isolate of pandemic A/California/E9/09 (H1N1) at a dosis of 1 × 103 TCID50 in PBS. After intubation, the virus was
administered by microspraying just above the tracheal bifurcation. Three days post-infection, lungs were collected, fixed, embedded in paraffin and further processed
as described in the Materials and Methods section. Viral antigen is stained reddish brown against a hematoxylin-stained blue background and shown for different
areas of the lower respiratory tract: (A,B) bronchiolar epithelial cells, (C,D) alveolar epithelial cells. Scale bars as indicated in each panel.
form of hSP-D also showed no activity with the highest doses of
hSP-D tested (2,000 ng/ml). Interestingly, the oligomeric forms
of pSP-D and iSP-D showed activity in the same range (50–
150 ng/ml) against A/PuertoRico/8/34 (H1N1), but there was a
major difference in HAI activity between their trimeric forms:
trimeric iSP-D was 13-fold less active than trimeric pSP-D. This
can, at least in part, be explained by the presence of the N-
glycan in the CRD of pSP-D which is absent in hSP-D. The
glycan’s presence would allow for both β- and γ-inhibition of
the virus, which may be critical for activity of the trimeric
forms, whereas the γ-inhibition may play a less critical role in
determining the activity of oligomeric forms. However, even iSP-
D trimers showed activity against this hSP-D-resistant strain and
this underlines the potential of trimeric iSP-D, or even collagen-
free NCRD fragments, as an hSP-D-based antiviral with profound
broad-range anti-IAV activity. To verify this, additional studies
with trimeric forms of iSP-D against a larger collection of IAVs
will be required. The viral aggregation properties of (oligomeric)
iSP-D were also examined and compared to those of hSP-D
(Figure 4). Full-length SP-D is able to bind and aggregate virus
particles, a well-known and important protection mechanism
that helps to prevent attachment of infectious IAV particles to
the lung epithelium and that promotes clearance by phagocytosis
(41). By the use of the pandemic strain A/Aichi/68 (H3N2) it
was determined that iSP-D exhibits significantly stronger IAV
aggregation properties as compared to hSP-D. Most likely this
is due to the distinct lectin-mediated affinity of iSP-D for the
N-linked oligosaccharides present on the surface of IAV (HA
glycosylation), resulting in faster aggregation and/or formation
of larger viral aggregates. Unfortunately, we were not able to
include pSP-D as reference although it was previously established
that pSP-D, like iSP-D, is more effective in viral aggregation as
compared to hSP-D (22).
In addition to HAI and viral aggregation, we also examined
the potential of iSP-D to reduce IAV infection with a previously
established IAV infection reduction in vitro assay using MDCK
cells (16). With this infection model, we tested and compared
the antiviral activity of pSP-D, hSP-D and iSP-D measured
against 4 IAV strains. It should be noted that for unknown
reasons the dose-dependency using this assay was restricted,
regardless of the IAV strain or SP-D preparation used, and none
of the viruses could be fully inhibited with the highest doses
of SP-D tested. Despite these assay limitations, it was clearly
established that compared to hSP-D, iSP-D was substantially
more effective and reached maximum inhibition levels much
higher than hSP-D. The inhibition profile is comparable to
that of pSP-D. Based upon these observations it can be
concluded that compared to hSP-D, iSP-D exhibits superior
IAV neutralizing activity in vitro, not only demonstrated
by HAI and viral aggregation, but also by its strongly
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FIGURE 7 | Validation of iSP-D as antiviral agent against pandemic IAV infection in mice. The protective potential of iSP-D against pandemic IAV infection in vivo was
assessed using the model as described in the materials and methods section and in Figure 6. Three different experiments were executed with 4 different conditions
within each experiment; group size was n = 6 per condition. Administration of iSP-D or hSP-D and viral challenge (A/California/E9/09 (H1N1) strain, 1 × 103 TCID50)
as described in the Materials and Methods. Three days after infection the average animal weights (% of weight at day 0) and average virus titers (log virus/g lung
tissue) were determined for all experimental groups. Experiment I, (A) (animal weight) and (B) (virus titers): antiviral effect of iSP-D-delivery (25 µg/animal) immediately
followed by viral challenge. Experiment II, (C) (animal weight) and (D) (virus titers): comparison of antiviral activity between 2 different batches of iSP-D and between
iSP-D and hSP-D (5.0 µg/animal). Experiment III, (E) (animal weight) and (F) (virus titers): the antiviral effect of iSP-D (25 µg/animal) delivered 1 day after or 1 day
before viral challenge. Statistical comparisons between experimental groups were made by Student’s two-tailed paired t-test. *p < 0.05; **p < 0.005; ***p < 0.0005.
improved ability to protect cell monolayers from infection
by IAV.
Overall, pSP-D appears slightly more active against all IAVs
tested as compared to iSP-D and this could be due to the
presence of the N-linked glycan in the CRD of pSP-D (lacking
in iSP-D) that was previously shown to contribute to the IAV
neutralizing properties of pSP-D (10, 19, 27). Consequently,
the antiviral properties of iSP-D might be further improved
by N-glycosylation of its CRD with a complex sialic acid-
rich oligosaccharide. It should be noted, however, that previous
studies have demonstrated that such modifications in the CRD
of hSP-D would not necessarily result in improved inhibitory
properties against IAV and likely involves additional, yet
unknown structural prerequisites present on the CRD of pSP-D
(21). Since iSP-D, in contrast to hSP-D, contains several porcine-
specific residues that have an impact on its interaction with IAV, it
can be speculated that iSP-Dmight be more suitable as a template
to perform N-glycosylation modification studies. Ultimately this
could result in the design and production of a highly active hSP-
D-based glycosylated mutant that exhibits both β-inhibitor and
γ-inhibitor-like properties, as demonstrated for pSP-D.
The importance of SP-D in protecting against IAV infection
in vivo has been demonstrated by the use of SP-D knockout mice
(SP-D -/-) that, upon infection by IAV, show increased lung virus
titers and weight loss as compared to wildtype mice (42, 43);
pulmonary instillation or over-expression of SP-D can correct
these effects (44, 45). The efficacy of SP-D-mediated clearance,
however, depends on the level of glycosylation of the viral
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spike proteins (12, 46). Pandemic IAV strains, in particular, are
associated with low expression of N-glycans in the head region
of their HAs and consequently, these strains are fairly resistant
for lectin-mediated binding and subsequent neutralization by
SP-D (38). Therefore, the efficacy of iSP-D in vivo was tested
with the 2009 pandemic H1N1 virus, not only because pandemic
IAVs are of special interest with regard to their implications
for human health, but also because this virus is resistant to
neutralization by endogenous wildtype SP-D. Weight loss of
infected mice was rapid and consistent and is considered to be an
important and sensitive indicator of diseases symptoms in mice.
Immunohistochemical analysis was performed on IAV-infected
mice and sections were stained for the presence of viral antigens.
Results indicated that H1N1pdm09 infection in mice induced
bronchiolitis but also alveolitis, with virus-staining in epithelial
cells lining the bronchioles and the alveoli (Figure 6). In a study
byQi et al. the samewas observed in amouse infectionmodel and
it was speculated that pandemic IAV-induced lower respiratory
pathology is associated with demonstrated low binding activity
of SP-D for pandemic IAVs (15). Moreover, these observations
also mimic closely pulmonary infections in humans caused by
pandemic IAV (e.g. 1918, 1957, 1968, and 2009) characterized by
distinct, substantial pathological changes of the lower respiratory
tract, associated with widespread infection of bronchiolar as well
as alveolar epithelial cells (47, 48).
With this pandemic IAV mouse infection model, the
protective potential of iSP-D was investigated in three different
experiments. The first experiment showed that H1N1pdm09
infection in mice induced profound weight loss and substantial
lung virus titers 3 days after challenge. If infection was
immediately preceded by treatment with iSP-D, animal weight
loss was completely prevented and lung virus titers were
significantly reduced, the first in vivo evidence for the protective
value of iSP-D against pandemic IAV. Administration of iSP-
D alone did not result in any changes in weight and behavior,
a preliminary indication that iSP-D does not have a direct
toxic effect after pulmonary delivery in mice. The second
experiment not only confirmed the protective effects, but also
showed that iSP-D batch-to-batch variations are very small.
Furthermore, by including a condition in which hSP-D was
administered instead of iSP-D, it was demonstrated that hSP-
D could not prevent infection-induced weight loss while only
a small reduction in lung virus titers was observed, consistent
with previous observations in vitro that showed resistance of
A/California/E9/09 (H1N1) for neutralization by hSP-D. In
contrast, iSP-D gained antiviral activity due to the pSP-D-
inspired mutations. Surprisingly, the average lung virus titers
obtained 3 days after infection were considerably higher in
the second (and third) experiment as compared to the first
experiment. This inconsistency remains difficult to explain since
the same batch, amount and volume of virus was used and the
route of administration was identical in all experiments. The
third experiment was designed to mimic more closely the use of
iSP-D as an antiviral for prophylactic or therapeutic applications
by expanding the interval between virus challenge and iSP-D
treatment (24 h). When treated with buffer, either 1 day before
or after virus challenge, all mice showed consistent weight loss
which was on average 9% at day 3 after infection. In contrast,
treatment with iSP-D 24 h before or after infection resulted
in only minor weight loss (2.7–3.3%) and these data suggest
that iSP-D can significantly reduce clinical symptoms caused
by pandemic IAV infection in mice, either prophylactically
or therapeutically. There was a major difference, however, in
lung virus titers. These were significantly lower in the group
that received treatment 1 day after inoculation and were only
slightly reduced when iSP-D was administered 1 day before
inoculation. Although the mechanism is not fully understood,
this could be due to the anti-inflammatory properties of iSP-
D. When administered prophylactically, iSP-D may contribute
to reduction of disease symptoms caused by IAV infection
but less capable in inhibiting viral replication, in contrast to
therapeutic application that results in significant reduction in
weight loss as well as lung virus titers. Another explanation for
the observed differences can be due to degradation of iSP-D (e.g.,
by pulmonary proteases) during the 24 h before virus challenge.
The slight reduction in lung virus titers seem to contradict the
observed prevention of weight loss. A possible explanation is that
this could be due to the anti-inflammatory effects exerted by iSP-
D and subsequent reduction of disease symptoms. In a follow-
up study we aim to include immunohistochemical analysis of
pulmonary inflammatory responses in order to determine how
these are affected after treatment with iSP-D.
The encouraging disease-reducing effects exerted by iSP-D,
especially in a therapeutic setting when only a single dose is
administered after infection with pandemic IAV, underline the
potency of iSP-D as a novel antiviral drug against a broad
range of IAV strains. As a novel inhalation drug, iSP-D could
contribute to reduction of disease severity, especially in settings
of pandemic outbreaks. This could prove important to protect
against potentially lethal IAV variants to bridge the time required
for the production of effective vaccines against such newly
emerging IAVs. The effect of iSP-D on lung virus titers in the
different challenge models is relatively modest. However, the
beneficial effects of iSP-D on the weight of infected animals are
very clear and suggest that the anti-inflammatory properties of
iSP-D contribute to the reduced morbidity. The protective effects
of iSP-D can be further enhanced by dose-optimization, drug
formulation, and repeated administration. Although iSP-D can
be considered as a human-based protein, such investigations
should run in parallel with safety studies with regard to possible
(immuno)toxic effects. It should be noted that, since iSP-D only
has 8 residues changed as compared to wildtype hSP-D (of a total
of 358 amino acids in a single polypeptide), severe complications
due to immunogenicity are less likely to occur compared to other,
non-human protein-based, antivirals.
Additional modifications of the molecular properties of iSP-D
can also be considered (e.g., N-glycosylations) to further enhance
the virus-neutralizing properties of iSP-D. Taken together,
our findings suggest that recombinant SP-D-based compounds
could generate a new class of versatile antiviral drugs against
seasonal and pandemic IAV and, considering their demonstrated
broad-range antimicrobial properties, with potential for effective
treatment of pulmonary infectious diseases caused by other
respiratory pathogens in humans.
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